Nemaura Medical Issues Presentation Pertaining to the use of Continuous Glucose Monitoring in COVID-19 Patients
August 19 2020 - 07:00AM
Business Wire
Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the
“Company”), a medical technology company focused on developing
micro-systems-based wearable diagnostic devices and currently
commercializing sugarBEAT®, its non-invasive and flexible
continuous glucose monitor (“CGM”), together with BEAT™diabetes, a
planned health subscription service designed to help people with
Type 2 diabetes and prediabetes through personalized lifestyle
coaching, today issued a presentation outlining how CGM is being
used by quarantined and hospitalised COVID-19 patients.
The Company has previously reported the uses of continuous
lactate measurements for the monitoring of diseases progression in
COVID-19 patients. Today the company issued a report outlining how
CGM has been used as an effective tool for the monitoring of
disease progression in both quarantined and hospitalised COVID-19
patients. This includes improvement in glycaemic control in persons
with Type 2 diabetes, monitoring and managing hyperglycaemia in
patients with COVID-19, and remote monitoring of glucose levels in
hospitalised COVID-19 patients leading to improved quality of care
without compromising the safety of medical professionals.
Both the CGM and CLM (continuous lactate monitoring) products
are based on Nemaura’s BEAT™ platform, which is designed to
non-invasively extract a number of analytes through the skin. By
adapting the sensor chemistry, algorithm and mobile app interface
initially developed for sugarBEAT®, the BEAT™ platform has the
potential to be utilized for several markets beyond glucose
monitoring and diabetes. Nemaura is evaluating the timelines for
bringing the CLM to market as a Class 2 approved Medical Device,
and the CGM device is a CE mark approved Class 2b medical device
planned for launch this calendar year in the UK and Germany.
The presentation may be accessed on the link below:
https://nemauramedical.com/wp-content/uploads/2020/08/Glucose-monitoring-in-Covid19-August.pdf
About Nemaura Medical, Inc.:
Nemaura Medical Inc. (NMRD) is a medical technology company
developing micro-systems-based wearable diagnostic devices and
currently commercializing sugarBEAT®, and proBEAT™. sugarBEAT®, a
CE mark approved Class IIb medical device, is a non-invasive and
flexible continuous glucose monitor (CGM) providing actionable
insights derived from real time glucose measurements and daily
glucose trend data, which may help people with diabetes and
pre-diabetes to better manage, reverse and prevent the onset of
diabetes. Nemaura has also submitted a PMA application for
sugarBEAT® to the U.S. FDA. proBEAT™ comprises a non-invasive
glucose monitor and a digital healthcare subscription service and
is due to be launched in the US as a general wellness product.
For more information visit: www.NemauraMedical.com.
Cautionary Statement Regarding Forward-Looking
Statements:
The statements in this press release that are not historical
facts may constitute forward-looking statements that are based on
current expectations and are subject to risks and uncertainties
that could cause actual future results to differ materially from
those expressed or implied by such statements. Those risks and
uncertainties include, but are not limited to, the launch of
proBEAT™ in the U.S., risks related to regulatory status and the
failure of future development and preliminary marketing efforts,
Nemaura’s ability to secure additional commercial partnering
arrangements, risks and uncertainties relating to Nemaura and its
partners’ ability to develop, market and sell proBEAT™, the
availability of substantial additional equity or debt capital to
support its research, development and product commercialization
activities, and the success of its research, development,
regulatory approval, marketing and distribution plans and
strategies, including those plans and strategies related to both
proBEAT™ digital health, and sugarBEAT®. There can be no assurance
that the company will be able to reach a part of or any of the
global market for CGM with its products/services. The FDA reserves
the right to re-evaluate their decision that proBEAT™ qualifies as
a general wellness product should it become aware of any issues
such as skin irritation or other adverse events from the device, as
well as any misuse impacting patient safety, and any other reason
as the FDA may see fit at its discretion to determine the product
does not fit the definition of a general wellness product. These
and other risks and uncertainties are identified and described in
more detail in Nemaura’s filings with the United States Securities
and Exchange Commission, including, without limitation, its Annual
Report on Form 10-K for the most recently completed fiscal year,
its Quarterly Reports on Form 10-Q, and its Current Reports on Form
8-K. Nemaura undertakes no obligation to publicly update or revise
any forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200819005328/en/
Investor Contact: Dave Gentry, CEO RedChip Companies Office:
1.800.RED.CHIP (733.2447) Cell: 407.491.4498 dave@redchip.com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Feb 2024 to Mar 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Mar 2023 to Mar 2024